Skip to content

US · PASG · BIOTECHNOLOGY

Passage Bio, Inc. (PASG) intrinsic value and stock valuation

$3.92as of 2026-11-21 · Mkt cap 14.81M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Passage Bio, Inc. DCF and intrinsic value

InvestorsCraft values PASG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PASG’s statements →

Passage Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Philadelphia, PA 19103 passagebio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-45.52M
20182025
Free cash flow
-$-31.51M
20182025
Total equity
$18.8M-42.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-43.15M-$-70.4M-$-100.14M-$-138.39M-$-185.73M
Net income-$-45.52M-$-64.77M-$-102.06M-$-136.12M-$-185.39M
EPSd-$-14.36M-$-21.45M-$-37.25M-$-50.04M-$-69.43M
Operating cash flow-$-31.51M-$-47.96M-$-78.26M-$-118.21M-$-126.88M
Capital expenditure$0.00-$-30K-$-150K-$-5.27M-$-25.64M
Free cash flow-$-31.51M-$-47.99M-$-78.41M-$-123.48M-$-152.52M
Total assets$62.3M$102.4M$150.5M$243.6M$355.1M
Total debt$24M$25.5M$26.3M$27.1M$0.00
Net debt-$-22.29M-$-12.1M$4.58M-$-7.49M-$-128.97M
Total equity$18.8M$61.3M$111.3M$201.4M$318.7M
Cash and short-term investments$46.3M$76.8M$114.3M$189.6M$315.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$730K$0.00$3.72M$0.00$0.00
Gross profit-$-730K$0.00-$-3.72M$0.00$0.00
Research and development expenses$23.3M$40.2M$59.6M$86.1M$117.7M
Selling, general and administrative expenses$19.9M$25M$41.6M$49.3M$60.1M
Other expenses-$-730K$5.23M-$-4.72M$3M$8M
Operating expenses$42.4M$70.4M$96.4M$138.4M$185.7M
Cost and expenses$43.2M$70.4M$100.1M$138.4M$185.7M
Interest income$2.3M$4.3M$5.6M$2.27M$340K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$730K$3.08M$3.72M$3.68M$1.54M
Ebitda-$-44.79M-$-62.09M-$-98.34M-$-131.72M-$-176.19M
Operating income-$-43.15M-$-70.4M-$-100.14M-$-138.39M-$-185.73M
Total other income/expenses, net-$-2.37M$5.63M-$-1.93M$2.27M$340K
Income before tax-$-45.52M-$-64.77M-$-102.06M-$-136.12M-$-185.39M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-45.52M-$-64.77M-$-102.06M-$-136.12M-$-185.39M
Weighted average shares outstanding$3.17M$3.02M$2.74M$2.72M$2.67M
Weighted average diluted shares outstanding$3.17M$3.02M$2.74M$2.72M$2.67M
Balance sheet
20252024202320222021
Cash and short-term investments$46.3M$76.8M$114.3M$189.6M$315.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$47.8M$78.8M$118M$197M$325.1M
Property, plant and equipment, net$14.3M$23.1M$32.2M$42.2M$23.8M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$14.5M$23.6M$32.6M$46.5M$30M
Total assets$62.3M$102.4M$150.5M$243.6M$355.1M
Accounts payable$1.11M$740K$1.3M$4.07M$9.45M
Short-term debt$3.57M$3.69M$3.37M$3.27M$0.00
Deferred revenue$13.8M$8.23M$0.00$0.00$0.00
Total current liabilities$23.1M$19.4M$16.3M$18.4M$29.5M
Long-term debt$20.4M$21.8M$22.9M$23.8M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$20.4M$21.8M$22.9M$23.8M$6.92M
Capital lease obligations$3.57M$25.5M$26.3M$27.1M$0.00
Total liabilities$43.5M$41.2M$39.3M$42.2M$36.4M
Common stock$0.00$10K$10K$10K$10K
Retained earnings-$-704.76M-$-659.24M-$-594.47M-$-492.41M-$-356.28M
Accumulated other comprehensive income (loss)$0.00$10K-$-40K-$-970K-$-410K
Total equity$18.8M$61.3M$111.3M$201.4M$318.7M
Total investments$0.00$39.2M$92.6M$155M$186.8M
Total debt$24M$25.5M$26.3M$27.1M$0.00
Net debt-$-22.29M-$-12.1M$4.58M-$-7.49M-$-128.97M
Cash flow statement
20252024202320222021
Net income-$-45.52M-$-64.77M-$-102.06M-$-136.12M-$-185.39M
Depreciation and amortization$860K$3.08M$3.72M$3.68M$1.54M
Stock-based compensation$3M$5.82M$10.9M$19M$32.7M
Change in working capital$4M$4.2M$5.34M-$-8.49M$11.4M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.88M-$-560K-$-2.79M-$-5.41M$2.2M
Net cash provided by operating activities-$-31.51M-$-47.96M-$-78.26M-$-118.21M-$-126.88M
Investments in property, plant and equipment$0.00-$-30K-$-150K-$-5.27M-$-25.64M
Acquisitions, net$1.17M$0.00$0.00$0.00$8M
Net cash used for investing activities$40.2M$55M$65.2M$25.2M-$-45.81M
Common stock issued$20K$8.74M$140K$430K$166.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$20K$8.87M$140K-$-1.35M$166.7M
Net change in cash$8.73M$15.9M-$-12.89M-$-94.36M-$-6.04M
Cash at end of period$46.3M$37.6M$21.7M$34.6M$129M
Operating cash flow-$-31.51M-$-47.96M-$-78.26M-$-118.21M-$-126.88M
Capital expenditure$0.00-$-30K-$-150K-$-5.27M-$-25.64M
Free cash flow-$-31.51M-$-47.99M-$-78.41M-$-123.48M-$-152.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Passage Bio, Inc.

        Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

        CEO
        William Chou
        Employees
        24
        Beta
        1.42

        Explore

        Frequently asked questions

        What is the intrinsic value of Passage Bio, Inc. (PASG)?

        InvestorsCraft does not currently publish an intrinsic value for PASG. How the IC value is calculated.

        Is PASG undervalued?

        InvestorsCraft does not publish an undervaluation signal for PASG at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.